Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial

van der Heijde, Désirée; Kivitz, Alan; H. Schiff, Michael; Sieper, Joachim; A. C. Dijkmans, Ben; Braun, Jürgen; Dougados, Maxime; D. Reveille, John; L. Wong, Robert; Kupper, Hartmut; C. Davis, John

doi:10.1002/art.21913

Public

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial

Shared by NobleBlocks on Jun 27, 2006 • 12:00 AM UTC

Authors:

Désirée van der Heijde

Alan Kivitz

Michael H. Schiff

Abstract

Abstract Objective To evaluate the safety and efficacy of adalimumab, a fully human recombinant IgG1 monoclonal antibody that specifically targets human tumor necrosis factor, in patients with active ankylosing spondylitis (AS). Methods This was a multicenter, randomized (2:1 ratio), double‐blind, p...

Discussions